Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Apple, Danaher, Novartis, AT&T and Estee Lauder

Read MoreHide Full Article

For Immediate Release

Chicago, IL – July 27, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. (AAPL - Free Report) , Danaher Corporation (DHR - Free Report) , Novartis AG (NVS - Free Report) , AT&T Inc. (T - Free Report) and The Estée Lauder Companies Inc. (EL - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for Apple, Danaher and Novartis

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple, Danaher and Novartis. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Apple have outperformed the S&P 500 over the past year (+57.8% vs. +40.6%), but the stock has lagged the broader Tech sector this year on lingering market worries about the company's standing in the post-Covid world.

The Zacks analyst sees the company's Q2 earnings report after the market's close on Tuesday (7/27) to reconfirm the momentum in its Services segment, driven by App Store, Cloud Services, Music, advertising and AppleCare.

An expanding App Store ecosystem, iPhones that support 5G, and a revamped iPad and Mac line-up of devices, are likely to boost Apple’s growth in the near term. Its ability to attract small developers is another major catalyst for growth. The company, however, refrained from providing any guidance due to the pandemic-related uncertainties.

(You can read the full research report on Apple here >>>)

Danaher shares have gained +31.3% over the last six months against the Zacks Diversified Operations industry’s gain of +19.2%. The Zacks analyst believes that the company is poised to gain from the Danaher Business System, buyouts and investment in product innovation in the quarters ahead.

For third-quarter 2021, Danaher anticipates core revenue growth in the mid to high-teens percentage range. Core sales are expected to benefit from pandemic-led tailwinds. A rise in costs and expenses, however, can be a major cause of concern for the company.

(You can read the full research report on Danaher here >>>)

Shares of Novartis have gained +5.7% in the past three months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +10.7%, however, the business is gradually recovering from the impacts of the pandemic. The Zacks analyst believes that momentum in key brands such as Cosentyx, Entresto, and Zolgensma, are likely to keep supporting Novartis’ growth in the quarters ahead.

New launches like Piqray and Mayzent are expected to boost sales and offset the resultant impact of the decline in sales of its legacy drugs. Novartis’ struggling Sandoz business also posted growth in the second quarter as the business is starting to stabilize. The oncology and generics businesses, however, are still reeling under the pressure of pandemic-led uncertainties.

(You can read the full research report on Novartis here >>>)

Other noteworthy reports we are featuring today include AT&T and Estée Lauder Companies.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.